Switch theme
Sign up to access all valuation multiples
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
1944
36.8K+
LTM Revenue $17.1B
LTM EBITDA $5.0B
$35.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Teva Pharmaceuticals has a last 12-month revenue (LTM) of $17.1B and a last 12-month EBITDA of $5.0B.
In the most recent fiscal year, Teva Pharmaceuticals achieved revenue of $4.7B and an EBITDA of $222M.
Teva Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Teva Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $17.1B | XXX | $4.7B | XXX | XXX | XXX |
| Gross Profit | $9.0B | XXX | $2.3B | XXX | XXX | XXX |
| Gross Margin | 53% | XXX | 49% | XXX | XXX | XXX |
| EBITDA | $5.0B | XXX | $222M | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 5% | XXX | XXX | XXX |
| EBIT | $4.5B | XXX | $961M | XXX | XXX | XXX |
| EBIT Margin | 26% | XXX | 20% | XXX | XXX | XXX |
| Net Profit | $3.0B | XXX | -$468M | XXX | XXX | XXX |
| Net Margin | 17% | XXX | -10% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $4.1B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Teva Pharmaceuticals's stock price is ILS 62 (or $18).
Teva Pharmaceuticals has current market cap of ILS 71.3B (or $20.4B), and EV of ILS 125B (or $35.7B).
See Teva Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $35.7B | $20.4B | XXX | XXX | XXX | XXX | $2.56 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Teva Pharmaceuticals has market cap of $20.4B and EV of $35.7B.
Teva Pharmaceuticals's trades at 7.6x EV/Revenue multiple, and 161.1x EV/EBITDA.
Equity research analysts estimate Teva Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Teva Pharmaceuticals has a P/E ratio of 6.9x.
See valuation multiples for Teva Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $20.4B | XXX | $20.4B | XXX | XXX | XXX |
| EV (current) | $35.7B | XXX | $35.7B | XXX | XXX | XXX |
| EV/Revenue | 2.1x | XXX | 7.6x | XXX | XXX | XXX |
| EV/EBITDA | 7.2x | XXX | 161.1x | XXX | XXX | XXX |
| EV/EBIT | 8.0x | XXX | 37.2x | XXX | XXX | XXX |
| EV/Gross Profit | 4.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 6.9x | XXX | -43.5x | XXX | XXX | XXX |
| EV/FCF | 21.6x | XXX | 167.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialTeva Pharmaceuticals's last 12 month revenue growth is 1%
Teva Pharmaceuticals's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $36K for the same period.
Teva Pharmaceuticals's rule of 40 is 10% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Teva Pharmaceuticals's rule of X is 31% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Teva Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1% | XXX | 91% | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Growth | 3% | XXX | 235% | XXX | XXX | XXX |
| Rule of 40 | 10% | XXX | 5% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 31% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $36K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 15% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 28% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Teva Pharmaceuticals acquired XXX companies to date.
Last acquisition by Teva Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Teva Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Teva Pharmaceuticals founded? | Teva Pharmaceuticals was founded in 1944. |
| Where is Teva Pharmaceuticals headquartered? | Teva Pharmaceuticals is headquartered in Israel. |
| How many employees does Teva Pharmaceuticals have? | As of today, Teva Pharmaceuticals has 36.8K+ employees. |
| Who is the CEO of Teva Pharmaceuticals? | Teva Pharmaceuticals's CEO is Mr. Richard D. Francis. |
| Is Teva Pharmaceuticals publicy listed? | Yes, Teva Pharmaceuticals is a public company listed on TAE. |
| What is the stock symbol of Teva Pharmaceuticals? | Teva Pharmaceuticals trades under TEVA ticker. |
| When did Teva Pharmaceuticals go public? | Teva Pharmaceuticals went public in 1961. |
| Who are competitors of Teva Pharmaceuticals? | Similar companies to Teva Pharmaceuticals include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Teva Pharmaceuticals? | Teva Pharmaceuticals's current market cap is $20.4B |
| What is the current revenue of Teva Pharmaceuticals? | Teva Pharmaceuticals's last 12 months revenue is $17.1B. |
| What is the current revenue growth of Teva Pharmaceuticals? | Teva Pharmaceuticals revenue growth (NTM/LTM) is 1%. |
| What is the current EV/Revenue multiple of Teva Pharmaceuticals? | Current revenue multiple of Teva Pharmaceuticals is 2.1x. |
| Is Teva Pharmaceuticals profitable? | Yes, Teva Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Teva Pharmaceuticals? | Teva Pharmaceuticals's last 12 months EBITDA is $5.0B. |
| What is Teva Pharmaceuticals's EBITDA margin? | Teva Pharmaceuticals's last 12 months EBITDA margin is 29%. |
| What is the current EV/EBITDA multiple of Teva Pharmaceuticals? | Current EBITDA multiple of Teva Pharmaceuticals is 7.2x. |
| What is the current FCF of Teva Pharmaceuticals? | Teva Pharmaceuticals's last 12 months FCF is $1.7B. |
| What is Teva Pharmaceuticals's FCF margin? | Teva Pharmaceuticals's last 12 months FCF margin is 10%. |
| What is the current EV/FCF multiple of Teva Pharmaceuticals? | Current FCF multiple of Teva Pharmaceuticals is 21.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
